search
Back to results

Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem

Primary Purpose

Hypertension, Craniotomy

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Diltiazem
Labetalol
Sponsored by
Mahidol University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, emergence, craniotomy, Hypertension during the emergence after craniotomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients who scheduled for craniotomy for tomor removal

Exclusion Criteria:

  • allergic to labetalol or diltiazem
  • Bradycardia < 60 beat/min
  • Second or third degree heart block
  • Severe asthma or severe COPD
  • Brain stem tumor

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Diltiazem

    Labetalol

    Arm Description

    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence

    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence

    Outcomes

    Primary Outcome Measures

    The number of the patients who have systolic blood pressure below 140 mmHg

    Secondary Outcome Measures

    mean doses of the study drugs
    the number of patients with Adverse Events as a Measure of Safety and Tolerability

    Full Information

    First Posted
    July 11, 2011
    Last Updated
    March 31, 2014
    Sponsor
    Mahidol University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01408524
    Brief Title
    Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
    Official Title
    A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2010 (undefined)
    Primary Completion Date
    November 2012 (Actual)
    Study Completion Date
    December 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Mahidol University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to determine the effectiveness of the antihypertensive drugs in the control of emergence blood pressure after tumor resection craniotomy; compared between labetalol (Avexa) and diltiazem (Herbessor). Also the investigators seek to determine the effective dose of the antihypertensive drugs and their side effects in Thai population.
    Detailed Description
    The study was randomized equivalence trial

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension, Craniotomy
    Keywords
    Hypertension, emergence, craniotomy, Hypertension during the emergence after craniotomy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    184 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Diltiazem
    Arm Type
    Active Comparator
    Arm Description
    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
    Arm Title
    Labetalol
    Arm Type
    Active Comparator
    Arm Description
    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
    Intervention Type
    Drug
    Intervention Name(s)
    Diltiazem
    Other Intervention Name(s)
    Herbessor
    Intervention Description
    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
    Intervention Type
    Drug
    Intervention Name(s)
    Labetalol
    Other Intervention Name(s)
    Avexa
    Intervention Description
    2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
    Primary Outcome Measure Information:
    Title
    The number of the patients who have systolic blood pressure below 140 mmHg
    Time Frame
    3 hours
    Secondary Outcome Measure Information:
    Title
    mean doses of the study drugs
    Time Frame
    3hr
    Title
    the number of patients with Adverse Events as a Measure of Safety and Tolerability
    Time Frame
    6 hour

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: patients who scheduled for craniotomy for tomor removal Exclusion Criteria: allergic to labetalol or diltiazem Bradycardia < 60 beat/min Second or third degree heart block Severe asthma or severe COPD Brain stem tumor
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Busara - Sirivanasandha, MD
    Organizational Affiliation
    Department of Anesthesiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem

    We'll reach out to this number within 24 hrs